Progress in Alzheimer’s and Parkinson’s Diseases

Передняя обложка
Abraham Fisher, Israel Hanin, Mitsuo Yoshinda
Springer Science & Business Media, 6 дек. 2012 г. - Всего страниц: 888
This book represents the fourth ina series of international conferences related to Alzheimer's (AD) and Parkinson's (PO) diseases. The first one took place in EHat, Israel in 1985; the second in Kyoto, Japan, in 1989; and the third in Chicago, IL, USA in 1993. This book incorporates the proceedings of the Fourth International Conference on Pro gress in Alzheimer's and Parkinson's Diseases, held in EHat, Israel, on May 18-23, 1997. This Conference was the 41st in the series of annual OHOLO Conferences sponsored by the Israel Institute for Biological Research (IIBR). It was also conducted under the aus pices of the Alzheimer's Association Ronald and Nancy Reagan Research Institute, USA. The Conference was attended by 550 participants from 28 countries, representing a broad spectrum of research interests; and included a well-balanced representation from aca demia, clinical institutions and pharmaceutical industry. The four-and-one-half day meeting served as an excellent medium for surveying the current preclinical and clinical develop ments in AD, PO, and other related disorders. The scientific program was divided into 24 oral sessions and daily poster sessions. The conference culminated in a round table discus sion. There were 122 talks and 161 posters. This book incorporates a combination of both.

Результаты поиска по книге

Содержание

Nicotinic Receptors as a New Target for Treatment of Alzheimers Disease
463
S 120242 a Cognitive Enhancer Interacts with Nicotinic Neurotransmission
469
Lewy Body Influence on Tacrine Efficacy
477
Tacrine Treatment in Parkinsons Disease Dementia
481
APP Localization and Trafficking in the Central Nervous System
487
The Cholinergic but Not the Serotonergic Phenotype of a New Neuronal Cell
495
The Molecular Basis Underlying the Discrete Activation of Signal Transduction
503
Muscarinic Modulation of BAmyloid Precursor Protein ẞAPP Processing
509

Neuronal Oxidative Stress Is a Common Feature of Alzheimers and Parkinsons
77
Intracerebroventricular Administration of BetaAmyloid Peptide 2535
89
Molecular Characterization of the Neuroprotective Activity of Salicylates
99
AgeRelated NaKATPase mRNA Expression and Alzheimers Disease
113
HBGAM a Novel Amyloid Associated Protein Is Present in Prion Related
121
Regulation of APP Metabolism by Protein Phosphorylation
133
Identification of Peptides Binding to Presenilin 1 by Screening of Random
141
Modulation by TNFa
149
Direct Evidence that Lactate Is an Obligatory Aerobic Energy Substrate
171
Comparative Study of Antioxidants Action on MembraneBound
177
Amyloidẞ Hypothesis of Alzheimers Disease
187
Anthracyclines and Amyloidosis
197
The Amino Terminus of the BAmyloid Peptide Contains an Essential Epitope
205
Animal Models of Amyloid Aggregation and Deposition
213
The Conformations of Tau Protein and Its Aggregation into Alzheimer Paired
222
Role of Neurofibrillary Degeneration in Alzheimers Disease
235
Cytoskeletal Protein Gene Expression after Neuronal Injury Recapitulates
241
Hyperphosphorylation of Tau in Apolipoprotein EDeficient Mice
251
Aẞ Induces Cell Death in PC12 Cells and TauTransfected Cho Cells but Only
257
Different Cognitive Profiles on Memory Tests in Parkinsons Disease
265
Neuropsychological Subtypes and Rate of Progression in Alzheimers Disease
271
Insulin Insulin Receptors and IgfI Receptors in PostMortem Human Brain
287
Demonstration of Aluminum in the Brain of Patients with Alzheimers Disease
293
Lipid Composition of Different Brain Regions in Patients with Alzheimers
301
Release from Proactive
309
Cognitive and NonCognitive Symptoms in Senile Dementia
317
Dementia Associated Sleep Disorders
323
Cognitive Impairment in Patients with Parkinsonism
337
Case Report on a Generalized Epilepsy in a Patient Suffering from Parkinsons
359
Effects of Progressive Neurological Disease on Interpersonal Relations between
371
Cognitive Deficits in Alzheimers Disease Parkinsons Disease
377
Recall of Ytzhak Rabins Assassination by Demented People
385
Genetic Aspects of Parkinsons Disease
393
A Chromosome 6qLinked Parkinsonism
401
Cytokines in Parkinsons Disease
407
NMethylRSalsolinol and RSalsolinol NMethyltransferase as Possible
413
Antioxidant and Cytoprotective Properties of Apomorphine
421
Toxicity of 1BnTIQ Endogenous Amine in the Brain in Mesencephalic Slice
429
Motor Fluctuation and Levodopa Absorption
439
The Rationale for Development of Cholinergic Therapies in AD
445
A New Avenue for Research into Neurobiological
451
Crystallographic Studies on Complexes of Acetylcholinesterase with the Natural
523
What Can Be Learned from the Use of HuAChE Mutants for Evaluation
531
Pharmacological and Transfection Studies
541
The NonCatalytic Role and Complex Management of Acetylcholinesterase
551
Antisense Oligodeoxynucleotide Dependent Suppression
557
Tacrine Reduces the Secretion of Soluble Amyloid BetaPeptides in
563
Do They Work?
571
The Preclinical Pharmacology of Metrifonate a LongActing and Well Tolerated
579
Increase in Cerebral Blood Flow and Glucose Utilization in Beneficial Effect
587
QuaternaryLipophilic Carbamates with Blood Brain Barrier Permeability
595
Characterization of C10 Substituted Analogues of Huperzine A as Inhibitors
601
Development and Uses of Small Molecule Ligands of TrkA Receptors
615
Molecular Cloning Transient Expression and Neurotrophic Effect for
627
PeptideMediated Neuroprotection
635
Gene Therapy of a Rodent Model of Parkinsons Disease Using
647
Memory Enhancing
653
Age Dependence of Muscarinic Plasticity in the Rat Hippocampus
661
AF64A and 192IgGSaporin
667
Molecular Mechanisms of AF64A Toxicity in the Cholinergic Neuron
675
Role of Nitric Oxide
681
Effect of AF64ANGF Treatment on ChAT mRNA Expression in
687
Induction Secretion and Pharmacological Regulation of BAPP in Animal
695
In Vivo Neurotoxicity of BAmyloid 140 in the Rat Hippocampus
705
Interval Hypoxic Training Prevents Oxidative Stress in Striatum and Locomotor
717
An a₂Adrenoceptor Agonist Clonidine Disrupts Attentional Performance
725
Functional Neuroimaging Reveals Decline from Premorbid Functioning in AD
733
Affinity to Monoamine Transporters in Rat Forebrain
739
A Peripheral Marker of Alzheimers Disease
747
alAntichymotrypsin and Apolipoprotein E Polymorphism in Alzheimers
757
Influence of the APOE Genoptype on Serum ApoE Levels in Alzheimers
765
Development of a Specific Diagnostic Test for Measurement of BAmyloid
773
Indices of Oxidative Stress in the Peripheral Blood of de Novo Patients with
779
Acylphosphatase Levels in Alzheimers Disease Cultured Skin Fibroblasts
787
APOE GenotypeRelated Blood Pressure in Senile Dementia
799
Changes in Cerebral Blood Flow Associated with Disease Staging and APOE
811
A Simple Procedure of Immunochemical Detection of Amyloid ẞ Proteins Using
823
Finding the Optimal Dose for Efficacy
829
Trial to Prevent Neurodegeneration in Persons Genetically Predisposed
841
Current Neurotransmitter Strategies in AD Drug Development
851
Harmonization of Drug Approval Guidelines in Alzheimers and Parkinsons
860
Авторские права

Другие издания - Просмотреть все

Часто встречающиеся слова и выражения

Библиографические данные